On August 9, 2023, PFIZER INC ($NYSE:PFE) announced their earnings results for the second quarter of FY2023 ending June 30, 2023. The total revenue for the quarter was USD 12.7 billion, the same as the same period in the previous year. Additionally, net income was announced to be USD 2.3 billion, with no fluctuation from the previous year.
This comes after a period of strong earnings throughout the last quarter. The stock opened at $35.6 and closed at 35.8, a 0.6% increase from its prior closing price. Despite the increase in revenue and earnings, Pfizer saw lower sales in the U.S., especially in its consumer health products, due to competitive market conditions. The company’s Chief Executive Officer, Albert Bourla, said that he was pleased with their performance in the second quarter and that the company remains focused on investing in innovative products and expanding its global reach.
He also cited increasing sales in emerging markets as a major factor in their success. Pfizer Inc continues to look for ways to expand its presence and capitalize on new opportunities in the pharmaceutical industry. With their impressive results this quarter, investors are optimistic about their future growth and are looking to take advantage of their potential performance in the coming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pfizer Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pfizer Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pfizer Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Pfizer Inc Intrinsic Value Calculator
At GoodWhale, we conducted an analysis of the fundamentals of PFIZER INC. Our proprietary Valuation Line determined the fair value of PFIZER INC share to be around $46.0. However, the stock is currently traded at $35.8, representing a significant discount of 22.1%. Therefore, it is clear that PFIZER INC is undervalued according to our analysis. With such an attractive entry point, this may be the perfect opportunity for investors to add PFIZER INC to their portfolios. More…
Risk Rating Analysis
Star Chart Analysis
In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.
– Astellas Pharma Inc ($TSE:4503)
Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.
Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”
Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.
Investors of Pfizer Inc should be encouraged by the company’s second quarter results for FY2023. Total revenue remained unchanged from the same period last year, while net income was also reported to be unchanged. This suggests that Pfizer’s performance has been steady, despite the challenges the industry has faced over the past year.
Going forward, investors should remain optimistic for the company’s future prospects as it continues to navigate the pandemic. With the increasing availability of vaccines and treatments, Pfizer’s reputation and financial outlook should continue to improve in the coming quarters.